Corporate Presentation
Obesity/MASH Survodutide
Survodutide* GCGR/GLP-1 receptor dual agonist
shows best-in-class potential in MASH Phase 2 trial
Phase 2 biopsy-driven trial in people with MASH¹
Participants showing improvement in MASH
without worsening of fibrosis (stages F1-F3):
83.0% with survodutide vs 18.2% with placebo
(p<0.0001)
Statistically significant improvement in liver
fibrosis with survodutide in secondary endpoint
ZEAL&
ZEALAND PHARMA
Boehringer
Ingelheim
Survodutide treatment did not show unexpected
safety or tolerability issues, including at the higher
dose of 6.0 mg
→ Further development in MASH planned
Full data to be presented at a scientific congress
in the first half of 2024
*Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries).
Source: 1) Boehringer Ingelheim press release February 26, 2024
MASH= metabolic dysfunction-associated steatohepatitis (formerly NASH=non-alcoholic steatohepatitis); CI=confidence interval; QW= once-weekly; GCG-glucagon; GLP-1-glucagon-like peptide-1
32
32View entire presentation